Generating simple classification rules to predict local surges in COVID-19 hospitalizations.
Yaesoubi R, You S, Xi Q, Menzies NA, Tuite A, Grad YH, Salomon JA.
Health Care Manag Sci. 2023 Jan 24. PMID: 36692583
Nick Menzies is Associate Professor of Global Health in the Department of Global Health and Population, and part of the core faculty of the Harvard Center for Health Decision Science. Professor Menzies uses decision science and quantitative research to understand the consequences of policies to combat major infectious diseases, and help design effective disease control programs when resources are limited.
Research
Professor Menzies combines empirical data with mathematical modeling to examine infectious disease control policy in high burden settings, currently focusing on the intersection of HIV and TB epidemics in sub-saharan Africa and other high-burden settings.
In his empirical research Nick has worked to improved the level of evidence on the resource requirements for HIV interventions in high burden settings, allowing for better budgeting of these large programs and allowing decision-makers to weigh the advantages of different implementation approaches. Nick is currently working on a multi-country study to understand the costs, cost drivers and efficiency determinants of routine immunization services. Other applied work has addressed the costs and benefits of expanding access to HIV screening and diagnosis in high prevalence settings.
The long-term population-level impacts of disease control policy are often difficult to assess empirically, especially for infectious diseases. Yet these are often the outcomes of interest when planning major public health investments. Through a number of studies Nick has used mathematical modelling - computer experiments which seek to recreate the underlying mechanisms generating health outcomes and resource utilization - to compare competing policy options being considered by HIV or TB control programs and directly inform the policy debate.
Professor Menzies's methodological interests include Bayesian approaches to calibrating simulation models, value of information analysis, the use of simulation models for causal inference, and approaches for synthesizing results from multiple models to inform policy.
Prior to joining Harvard Nick worked with the Global AIDS Program at the U.S. Centers for Disease Control and Prevention, conducting economic evaluation and implementation research on HIV/AIDS control interventions in countries supported by the President's Emergency Plan for AIDS Relief (PEPFAR).
Yaesoubi R, You S, Xi Q, Menzies NA, Tuite A, Grad YH, Salomon JA.
Health Care Manag Sci. 2023 Jan 24. PMID: 36692583
Portnoy A, Clark RA, Quaife M, Weerasuriya CK, Mukandavire C, Bakker R, Deol AK, Malhotra S, Gebreselassie N, Zignol M, Sim SY, Hutubessy RCW, Baena IG, Nishikiori N, Jit M, White RG, Menzies NA.
PLoS Med. 2023 Jan. 20(1):e1004155. PMID: 36693081
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA.
medRxiv. 2022 Nov 23. PMID: 36451882
Quaife M, Medley GF, Jit M, Drake T, Asaria M, van Baal P, Baltussen R, Bollinger L, Bozzani F, Brady O, Broekhuizen H, Chalkidou K, Chi YL, Dowdy DW, Griffin S, Haghparast-Bidgoli H, Hallett T, Hauck K, Hollingsworth TD, McQuaid CF, Menzies NA, Merritt MW, Mirelman A, Morton A, Ruiz FJ, Siapka M, Skordis J, Tediosi F, Walker P, White RG, Winskill P, Vassall A, Gomez GB.
Epidemics. 2022 12. 41:100648. PMID: 36343495
Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA.
Lancet Glob Health. 2022 11. 10(11):e1646-e1654. PMID: 36240830
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender CJ, Centner H, Engelthaler DM, Crudu V, Cohen T, Menzies NA.
Int J Tuberc Lung Dis. 2022 10 01. 26(10):963-969. PMID: 36163669
Chitwood MH, Russi M, Gunasekera K, Havumaki J, Klaassen F, Pitzer VE, Salomon JA, Swartwood NA, Warren JL, Weinberger DM, Cohen T, Menzies NA.
PLoS Comput Biol. 2022 08. 18(8):e1010465. PMID: 36040963
Li Y, de Macedo Couto R, Pelissari DM, Costa Alves L, Bartholomay P, Maciel EL, Sanchez M, Castro MC, Cohen T, Menzies NA.
Lancet Glob Health. 2022 10. 10(10):e1463-e1472. PMID: 36049488
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA.
Clin Infect Dis. 2022 Jun 20. PMID: 35717642
Sileo KM, Wanyenze RK, Schmarje Crockett K, Naigino R, Ediau M, Lule H, Kalichman SC, Lin CD, Menzies N, Bateganya MH, Kiene SM.
BMJ Open. 2022 05 31. 12(5):e054936. PMID: 35641013
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment, according to a new report.
A new statistical model developed by researchers from Harvard Chan School and Yale School of Public Health provides a tool for analyzing COVID-19 outcomes and making near real-time projections at a local level about disease spread.
But a greater focus on testing and treatment, particularly among immigrants, could speed the disease’s decline, study finds May 21, 2018 – Although tuberculosis (TB) is on the wane in the U.S., there’s little chance that the nation…
July 21, 2016 -- As new vaccines are introduced—some of them quite costly—accurate information on the cost and financing of national immunization programs can be lacking. Research and a new website developed at Harvard T.H. Chan School of…